The inhibition of Src enhanced the cytotoxicity of cisplatin and paclitaxel in drug-sensitive ovarian cancer cells and restores sensitivity in drug resistant cells, and these effects are dependent on caspase-3 activity [63]. The gene discussed is SRC; the disease is ovarian carcinoma.